Gavazova et al. [103] conducted a prospective observational study evaluating 30 RA patients with obesity and T2DM treated with GLP-1 RAs for 6 months, without concomitant conventional or biologic disease-modifying anti-rheumatic drugs (DMARDs). This evidence concerns the gene GLP1R and obesity disorder.